Publications by authors named "Masey Ross"

Claim this Profile
T
T-cell immune checkpoint inhibition plus hypomethylation for locally advanced HER2-negative breast cancer: a phase 2 neoadjuvant window trial of decitabine and pembrolizumab followed by standard neoadjuvant chemotherapy.
Harry D Bear, Xiaoyan Deng, Dipankar Bandyopadhyay, Michael Idowu, Taylor M Jenkins, Masey Ross

J Immunother Cancer· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of web-based decision support to improve informed choice for chemoprevention: a qualitative analysis of pre-implementation interviews (SWOG S1904).
Alissa M Michel, Haeseung Yi, Jacquelyn Amenta, Nicole Collins, Anna Vaynrub, Maria Grosse Perdekamp, Masey Ross

BMC Med Inform Decis Mak· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Longitudinal associations among physical activity and sitting with endocrine symptoms and quality of life in breast cancer survivors: A latent growth curve analysis.
Alexander R Lucas, Youngdeok Kim, Autumn Lanoye, R Lee Franco, Arnethea L Sutton, Masey Ross

Cancer Med· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Physical activity, health-related quality of life, and adjuvant endocrine therapy-related symptoms in women with hormone receptor-positive breast cancer.
Vanessa B Sheppard, Chiranjeev Dash, Sarah Nomura, Arnethea L Sutton, Robert Lee Franco, Masey Ross

Cancer· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nab-Paclitaxel: A New Standard of Care in Neoadjuvant Therapy of High-Risk Early Breast Cancer?
Masey Ross, Charles E Geyer

J Clin Oncol· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Co-administration of the mTORC1/TORC2 inhibitor INK128 and the Bcl-2/Bcl-xL antagonist ABT-737 kills human myeloid leukemia cells through Mcl-1 down-regulation and AKT inactivation.
Mohamed Rahmani, Mandy Mayo Aust, Elisa Hawkins, Rebecca E Parker, Masey Ross

Haematologica· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vascular KCNQ (Kv7) potassium channels as common signaling intermediates and therapeutic targets in cerebral vasospasm.
Bharath K Mani, James O'Dowd, Lalit Kumar, Lioubov I Brueggemann, Masey Ross

J Cardiovasc Pharmacol· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis